A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin
Completed
National Cancer Institute (NCI)
Phase 2
The objectives of this study are to determine the response rate to 9-AC in patients with
advanced ovarian cancer who have recurrent disease after paclitaxel- and cisplatin-based
chemotherapy regimens.
A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors
Completed
National Cancer Institute (NCI)
Phase 1
This study examines a 96 hour infusion schedule of irinotecan alternating with 72 hour
drug-free intervals in patients with solid tumors in order to determine the maximum tolerated
dose of this regimen.
Aminocamptothecin in Treating Patients With T-cell Lymphoma
Completed
National Cancer Institute (NCI)
Phase 2
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients
with advanced cutaneous T-cell lymphoma.
Aminocamptothecin in Treating Patients With T-cell Lymphoma
Completed
Yale University
Phase 2
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients
with advanced cutaneous T-cell lymphoma.
Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer
Completed
Eastern Cooperative Oncology Group
Phase 2
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients
with recurrent or unresectable epithelial ovarian cancer that has been previously treated
with platinum-based chemotherapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.